Department of Orthopedics, 1st Affiliated Hospital and Orthopedic Institute, Soochow University, Suzhou 215007, Jiangsu, China.
Med Oncol. 2013 Jun;30(2):529. doi: 10.1007/s12032-013-0529-4. Epub 2013 Mar 16.
Chordoma is a rare and invasive malignant tumor which primarily relies on surgical treatments. Anticipation of its recurrence and patient survival longevity has been a critical issue of the treatments. This retrospective study examined the survivin expression of sacral chordoma in 30 patients undergoing surgery in our hospital from January 2000 to July 2010, and compared it with chordoma recurrence. Survivin expression was 70 % positive in 30 patients. The positive expression of survivin with recurrence was significantly higher than that without recurrence (p = 0.017) and was inversely related to the continuous disease-free survival time (p < 0.001). Survivin expression was associated with recurrence. The correlation suggested that the survivin expression could be used as an independent predictor of recurrence and could be a potential bio-target gene of angiogenesis in sacral chordoma.
脊索瘤是一种罕见的侵袭性恶性肿瘤，主要依赖于手术治疗。预测其复发和患者生存时间一直是治疗的关键问题。本回顾性研究分析了我院 2000 年 1 月至 2010 年 7 月 30 例行手术治疗的脊索瘤患者的生存素表达情况，并与脊索瘤复发进行了比较。30 例患者中生存素表达阳性率为 70%。生存素阳性表达与复发显著相关（p = 0.017），与无瘤生存时间呈负相关（p < 0.001）。生存素表达与复发相关，提示生存素表达可作为脊索瘤复发的独立预测因子，也可能是骶骨脊索瘤血管生成的潜在生物靶基因。
